Outcomes in COVID-19 glenzocimab studies

All studies   Serious outcomes   Recovery   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -60% 1 62 Improvement, Studies, Patients Relative Risk RCTs -60% 1 62 Early -60% 1 62 Glenzocimab for COVID-19 c19early.org November 2025 Favorsglenzocimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -49% 1.49 [0.53-4.20] no recov. 7/30 5/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.46 Early treatment -49% 1.49 [0.53-4.20] 7/30 5/32 49% higher risk All studies -49% 1.49 [0.53-4.20] 7/30 5/32 49% higher risk 1 glenzocimab COVID-19 recovery result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.46 Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Early treatment -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk All studies -60% 1.60 [0.76-3.36] 12/30 8/32 60% higher risk 1 glenzocimab COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors glenzocimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pottecher (DB RCT) -60% 1.60 [0.76-3.36] progression 12/30 8/32 Improvement, RR [CI] Treatment Control Pottecher (DB RCT) -54% 1.54 [0.77-3.07] progression 13/30 9/32 Pottecher (DB RCT) -49% 1.49 [0.53-4.20] no recov. 7/30 5/32 Pottecher (DB RCT) -413% 5.13 [0.26-103] no recov. 2/30 0/32 Glenzocimab COVID-19 outcomes c19early.org November 2025 Favors glenzocimab Favors control